Ranbaxy launches anti-platelet agent Prasugrel in India

Gurgaon-based Ranbaxy Laboratories Ltd has launched a generic version of Prasugrel in India. The product called Prasita is an antiplatelet agent for prevention of atherothrombotic events in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Prasita is solely marketed by Ranbaxy in India.

Following the April 2009 launch of Olvance (olmesartan medoxomil), an antihypertensive originally discovered by Tokyo-based Daiichi Sankyo Company Ltd, Prasita is the second product from the Daiichi Sankyo portfolio to be introduced in India through the Ranbaxy business network. Ranbaxy will create awareness, understanding and acceptance of the new antiplatelet therapy among the target audiences in the country.

On Thursday, Ranbaxy's shares ended 1.34% up at Rs424 on the Bombay Stock Exchange, while the benchmark Sensex closed 1.59% up at 16,922 points.

User

Orchid to acquire US-based marketing company Karalex Pharma

The Chennai-based generic pharma major, Orchid Chemicals & Pharmaceuticals Ltd has entered an agreement to acquire Karalex Pharma, a US-based generic marketing and sales service company, through an all-cash deal for an undisclosed amount. The transaction is expected to close by this month subject to customary closing conditions. Through this acquisition, Orchid has created its presence in the front-end US market and will be able to reach its generic products to the US customers directly.

Headquartered in New Jersey, Karalex Pharma is a leading provider of generic pharmaceuticals focused exclusively on the US healthcare market. Orchid is a leading pharmaceutical company involved in the development, manufacture and marketing of diverse bulk actives, formulations and nutraceuticals.

On Thursday, Orchid's shares ended 4.61% up at Rs151 on the Bombay Stock Exchange, while the benchmark Sensex closed 1.59% up at 16,922 points.

User

Rollbacks & about-turns: Will the government sink the proposed public float norms?

The holy cows of our corporate world do not want the proposed minimum 25% public float norms to...

Premium Content
Monthly Digital Access

Subscribe

Already A Subscriber?
Login
Yearly Digital+Print Access

Subscribe

Moneylife Magazine Subscriber or MSSN member?
Login

Yearly Subscriber Login

Enter the mail id that you want to use & click on Go. We will send you a link to your email for verficiation

We are listening!

Solve the equation and enter in the Captcha field.
  Loading...
Close

To continue


Please
Sign Up or Sign In
with

Email
Close

To continue


Please
Sign Up or Sign In
with

Email

BUY NOW

The Scam
24 Year Of The Scam: The Perennial Bestseller, reads like a Thriller!
Moneylife Magazine
Fiercely independent and pro-consumer information on personal finance
Stockletters in 3 Flavours
Outstanding research that beats mutual funds year after year
MAS: Complete Online Financial Advisory
(Includes Moneylife Magazine and Lion Stockletter)